Evidence map›Paper›PMID 24015116›Full record

ArticleSleep medicine clinics2013

Optimizing the Pharmacologic Treatment of Insomnia: Current Status and Future Horizons.

Jared Minkel, Andrew D Krystal

Abstract read
In one paragraph

Article in Sleep medicine clinics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Lorazepam use during clinical trials of adults with bipolar mania episodes.Contemporary clinical trials communications · 2023
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Sleep therapeutics and neuropsychiatric illness.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Review
  12. Review
  13. Decline in cardiorespiratory fitness and odds of incident sleep complaints.Medicine and science in sports and exercise · 2015
    Article
  14. Article
  15. Suvorexant: The first orexin receptor antagonist to treat insomnia.Journal of pharmacology & pharmacotherapeutics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jared Minkel
Andrew D Krystal

Funding

3/3-Improving Depression Outcome by Adding CBT for Insomnia to AntidepressantsR01MH079256 · NIMH · DUKE UNIVERSITY · PI KRYSTAL, ANDREW D · 2008 to 2012
$1.1M
2/3-Reducing Suicide Ideation Through Insomnia Treatment (REST-IT)R01MH095780 · NIMH · DUKE UNIVERSITY · PI KRYSTAL, ANDREW D · 2012 to 2016
$904k
NIMH NIH HHS R01 MH079256NIMH NIH HHS R01 MH095780
6 · The paper itself

Abstract

A number of medications are available for treating patients with insomnia. These medications include agents approved as insomnia therapies by the U.S. Food and Drug Administration (FDA), agents approved by the FDA for another condition that are used "off-label" to treat insomnia, and agents available "over-the-counter" that are taken by individuals with insomnia. These agents differ in their properties, their safety and efficacy when used for different insomnia patient subtypes, and the available data on their efficacy and safety in these subtypes. As a result, optimizing the medication treatment of insomnia for a given patient requires that the clinician select an agent for use which has characteristics that make it most likely to effectively and safely address the type of sleep difficulty experienced by that individual. This article is intended to assist clinicians and researchers in carrying out this optimization. It begins by reviewing the basic characteristics of the medications used to treat insomnia. This is followed by a review of the fundamental ways that individuals with insomnia may differ and affect the choice of medication therapy. This review includes discussions that illustrate how to best choose a medication based on the characteristics of the available medications, the key differences among insomnia patients, and the available research literature. Lastly, we discuss future directions for the optimizing pharmacologic management of insomnia. It is hoped that the treatment tailoring methods discussed herein serve as a means of improving the clinical management of insomnia and, thus, improve the lives of the many patients who suffer from this common and impairing condition.

Indexed as

InsomniaPharmacotherapy

Identifiers

PMID24015116
PMCPMC3763861

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.